BACKGROUND Chronic kidney disease is associated with an increased risk of both bleeding and ischemic
C hronic kidney disease increases the risk of both thromboembolism and bleeding (1) (2) (3) (4) (5) (6) (7) . Prior studies have investigated the effectiveness of treating patients with varying degrees of renal impairment and antithrombotic agents (8, 9) and with non-vitamin K antagonist oral anticoagulants compared with warfarin among patients with atrial fibrillation (10) (11) (12) (13) (14) (15) (16) (17) . Full anticoagulation, even without acetylsalicylic acid (ASA, or aspirin), increases bleeding risks in the presence of renal dysfunction (4-7). Higher age and the prevalent comorbidities associated with vascular disease also increase both bleeding risks and adverse cardiovascular outcomes. Non-vitamin K antagonist oral anticoagulants vary in their extent of renal excretion, with 25% to 80% of the drug excreted unchanged in the urine (15) (16) (17) . Hence, the balance of risk versus benefit for antithrombotic combinations may be altered in the presence of renal dysfunction.
In the COMPASS (Cardiovascular OutcoMes for
People using Anticoagulation StrategieS) trial, we hypothesized that one-quarter of the full anticoagulant dose of rivaroxaban (2.5 mg twice daily [bd] ) and ASA together, or one-half dose of rivaroxaban alone (5 mg bd) would be superior to ASA alone for the prevention of major vascular events in patients with chronic vascular disease (18) . In the COMPASS trial overall, rivaroxaban 2.5 mg bd plus aspirin, compared with aspirin alone, reduced cardiovascular outcomes and increased major bleeding in patients with stable atherosclerotic vascular disease (19) (20) (21) . In contrast rivaroxaban 5 mg twice daily did not reduce cardiovascular outcomes and increased major bleeding (19) .
This report examines the safety and efficacy of reduced dose anticoagulation (rivaroxaban) in combination with aspirin in the COMPASS trial (the "dual pathway COMPASS regimen") (22), versus ASA alone in patients who are in sinus rhythm but at increased vascular risk. As rivaroxaban 5 mg bd without ASA did not reduce cardiovascular outcomes, the focus of this paper is on the comparison between the dualpathway COMPASS regimen and ASA. (18, 19) .
METHODS
The details of inclusion and exclusion criteria have been published previously (18, 19) .
Patients included in the COMPASS trial had chronic "stable" CAD and/or peripheral artery disease (18) .
For CAD patients age younger than 65 years, additional risk factors were required, and these comprised documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors. The additional risk factors included a glomerular filtration rate (GFR) <60 ml/min (but those with a GRF <15 ml/min were excluded);
hence, the population was enriched for moderately severe renal dysfunction.
OUTCOMES. The pre-specified primary outcome of the trial was the composite of cardiovascular death, stroke, or MI; in this report, the individual endpoints are also reported and strokes are categorized as hemorrhagic or ischemic/unknown. The safety outcomes were major bleeding (by modified International Society on Thrombosis and Haemostasis criteria), fatal bleeding, and intracranial bleeding (18, 19) .
Patients in the COMPASS trial were categorized by severity of chronic renal disease according to the estimated (CKD-Epi) GFR <60 and $60 ml/min and the relation between renal dysfunction and outcomes was also investigated as a continuous function of GFR.
STATISTICAL METHODS. Analyses were conducted according to the intention-to-treat principle. Annualized event rates were calculated as number of patients with an outcome per total number of patientyears of follow-up. Event rates were calculated within the deciles of estimated glomerular filtration rate (eGFR) and displayed in a plot along with a parametric cubic spline smoothing function. Survival analyses were based on the time to a first event.
Stratified Cox proportional hazards regression models were used to compare the effects of antithrombotic regimens within categories of eGFR. Significance was tested using stratified log-rank tests. Interaction between the effect of treatment with rivaroxaban/ aspirin and eGFR was tested in a stratified Cox model fit to all patients. All reported p values are 2-sided.
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Analyses were performed using SAS software for Linux, version 9.4 (SAS Institute Inc., Cary, North Carolina). Table 1 ). Tests for subgroup interaction by the categories of renal function were not significant for the primary efficacy outcomes and for the primary safety (bleeding) analysis ( Table 2) .
RESULTS
From
The rates of stroke of any cause were reduced for the rivaroxaban 2.5 mg bd plus aspirin group versus aspirin for those with GFR $60 ml/min (0.9% and 1.3%, respectively; HR: 0.67; 95% CI: 0.48 to 0.92) and GFR <60 ml/min (1.0% and 2.3%, respectively; HR:
0.42; 95% CI: 0.25 to 0.70). There were very few strokes among the 243 patients with a GFR <30 ml/min (none in the rivaroxaban treatments and 3 in the aspirin-only arm) (Online Table 1 ). Ischemic or uncertain strokes were also reduced for those treated with rivaroxaban 2.5 mg bd plus aspirin versus aspirin alone with GFR <60 ml/min (0.7% and 2.2%, respectively, HR: 0.31; 95% CI: 0.17 to 0.57) and for GFR $60 ml/min (0.8% and 1.2%, respectively, HR:
0.62; 95% CI: 0.44 to 0.87). There were no patients with ischemic or uncertain strokes with GFR <30 ml/min in the rivaroxaban plus aspirin treatment group, and 3 in the aspirin-only group (Online Table 1 ).
Cardiovascular death was reduced for the rivaroxaban 2.5 mg bd plus aspirin group versus aspirin for those with GFR $60 ml/min (1.3% and 1.7%, respectively, HR: 0.73; 95% CI: 0.56 to 0.96) and for GFR <60 ml/min (3.5% and 3.9%, respectively, HR:
0.88; 95% CI: 0.64 to 1.20) .
The consistency of treatment effects for the efficacy outcomes by GFR status is given in the Central Illustration for rivaroxaban 2.5 mg bd plus aspirin versus aspirin. Throughout the range in GFR, the rivaroxaban 2.5 mg plus aspirin patients had consistently lower primary efficacy outcomes. Tests for statistical interactions were not significant ( Table 2) . Values are mean AE SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; eGFR ¼ estimated glomerular filtration rate; NSAID ¼ nonsteroidal anti-inflammatory drug; PPI ¼ proton pump inhibitors.
Major bleeding was more frequent with reduced renal function, irrespective of treatment strategy (Central Illustration).
Considering the randomized treatments, major bleeding was more frequent in those randomized to rivaroxaban 2.5 mg plus aspirin versus aspirin alone in those with GFR $60 ml/min (2.9% rivaroxaban plus aspirin 1.6% aspirin, HR: 1.81; 95% CI: 1.44 to 2.28) and in those with GFR <60 ml/min (3.9% rivaroxaban plus aspirin, 2.7% aspirin, HR: 1.47; 95% CI: 1.05 to 2.07). Major bleeds were too few to calculate a reliable hazard ratio for those with a GRF <30 ml/min (3 on aspirin alone and 1 with rivaroxaban 2.5 mg bd plus aspirin [Online Table 1] ).
Although bleeding rates were higher for those with renal dysfunction, irrespective of treatment strategy (Table 2) , the absolute difference in rates of major bleeding was similar for those with GRF <60 ml/min (0.7% per annum) compared with GRF $60 ml/min (0.7% per annum) (Figure 1 ).
The consistency of the impact of the randomized treatment on major bleeding according to renal dysfunction is indicated in the Central Illustration.
Throughout the range in GFR, the rivaroxaban 2.5 mg plus aspirin patients had consistently higher rates of major bleeding, with no evidence of a divergence of the curves with lower GFR (Central Illustration).
The interaction terms were nonsignificant. The consistency of treatment effects according to GFR $60 or <60 ml/min is given in Figure 1 . Rates of COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) primary efficacy outcome (cardiovascular death, stroke, or myocardial infarction; left) and major bleeding (right) according to estimated glomerular filtration rate (eGFR) (with 95% confidence interval). To define the relation between the severity of renal dysfunction (as estimated by eGFR), a continuous plot is provided over the range of eGFR in the COMPASS study for the primary outcome and for bleeding. Throughout the range in eGFR, rivaroxaban plus aspirin demonstrates fewer primary outcome events than aspirin plus placebo (cardiovascular death, stroke, or myocardial infarction, left) but consistently more bleeding (right). The lines (aspirin: red, rivaroxaban: blue) show the relation between event rates and eGFR;
cross-hatched areas show 95% CI bounds (aspirin: red, rivaroxaban: blue).
Fox et al. Table 2) .
Symptomatic bleeding into a critical organ occurred with a frequency of 0.3% per annum with ASA (GFR $60 ml/min), and 0.4% per annum with ASA (GFR <60 ml/min) ( Table 2 ). This compares with 0.4% per annum with rivaroxaban plus aspirin (GFR $60 ml/min), and 0.6% per annum with rivaroxaban and aspirin (GFR <60 ml/min) ( Table 2) . The COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) primary efficacy outcome (cardiovascular death, stroke, or myocardial infarction; left) is consistently and significantly less frequent with rivaroxaban plus aspirin compared with aspirin plus placebo. Conversely, rivaroxaban plus aspirin compared with aspirin plus placebo shows more bleeding (right), but there is no evidence that the excess in bleeding is more marked in those with estimated glomerular filtration rate (eGFR) <60 ml/min. CI ¼ confidence interval; HR ¼ hazard ratio. 
